Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 10Genitourinary 6Gastrointestinal 6Thoracic 5Breast 5Gynecologic 4Sarcoma 1Other hematologic neoplasm 1Other 1Lymphoid 1Head & Neck 1Dermatologic 1

Conditions

Lymphoma 9Lymphoma, Non-Hodgkin 7Lymphoma, Follicular 6Lymphoma, Large B-Cell, Diffuse 5Recurrence 4Leukemia, Lymphocytic, Chronic, B-Cell 4Neoplasms 3Melanoma 3Lymphoma, B-Cell 3Hodgkin Disease 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Neoplasms by Site 2Neoplasms by Histologic Type 2Multiple Myeloma 2Lymphoproliferative Disorders 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Merkel Cell 2Triple Negative Breast Neoplasms 1Sezary Syndrome 1Sarcoma, Clear Cell 1Pancreatic Neoplasms 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Mycosis Fungoides 1Microsatellite Instability 1Lymphoma, T-Cell, Cutaneous 1

Interventions

pembrolizumab 5Gemcitabine 5Albumin-Bound Paclitaxel 5Specimen Handling 4Nivolumab 4Magnetic Resonance Spectroscopy 4Cyclophosphamide 4Bevacizumab 4venetoclax 3spartalizumab 3abemaciclib 3Sirolimus 3Pemetrexed 3Paclitaxel 3Leucovorin 3Ipilimumab 3Fluorouracil 3Doxorubicin 3Cisplatin 3Bortezomib 3130-nm albumin-bound paclitaxel 3manganese chloride 2fludarabine phosphate 2fludarabine 2copanlisib 2Taxes 2Midazolam 2Irinotecan 2Interleukin-2 2Immunoglobulin G 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × atezolizumab × Lymphoid × Clear all
NCT04167137 2024-05-03

Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants

Synlogic

Phase 1 Terminated
32 enrolled 19 charts
Lymphoid

Lymphoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡